[Alcohol dependence and opioid receptor -Pharmacological profile of nalmefene].


Journal

Nihon yakurigaku zasshi. Folia pharmacologica Japonica
ISSN: 0015-5691
Titre abrégé: Nihon Yakurigaku Zasshi
Pays: Japan
ID NLM: 0420550

Informations de publication

Date de publication:
2020
Historique:
entrez: 8 5 2020
pubmed: 8 5 2020
medline: 13 8 2020
Statut: ppublish

Résumé

Alcohol dependence is one of the psychiatric disorders affecting over 1 million people in Japan. Mesolimbic dopamine neuron projecting from ventral tegmental area to nucleus accumbens (Reward system) plays important roles in alcohol dependence including other dependence. Accumulating evidence indicates that the endogenous opioid system regulate this reward system. That is, alcohol stimulates the release of endogenous opioid peptides such as β-endorphin and dynorphin in the brain. β-endorphin activates μ-opioid receptor leading to euphoric mood and positive reinforcement, while dynorphin activates κ-opioid receptor leading to dysphoric mood and negative reinforcement. These euphoric/dysphoric mood and reinforcement effects via endogenous opioid systems are suggested to be implicated in repeated alcohol intake in patients with alcohol dependence. Nalmefene acts as an antagonist at μ- and δ-opioid receptor and a partial agonist at κ-opioid receptor. Preclinical studies have shown that nalmefene reduced the alcohol intake in alcohol preference rats. In clinical trials, as-needed use of nalmefene with psychosocial support reduced the number of heavy-drinking days and total alcohol consumption. These results suggest that nalmefene modulates the alcohol-induced euphoric/dysphoric mood via opioid system and thereby contribute to reduction in alcohol consumption in patients with alcohol dependence. Here, we summarize the implications of opioid system in alcohol dependence and pharmacological profiles of nalmefene in preclinical and clinical studies.

Identifiants

pubmed: 32378631
doi: 10.1254/fpj.19139
doi:

Substances chimiques

Narcotic Antagonists 0
Receptors, Opioid 0
Naltrexone 5S6W795CQM
nalmefene TOV02TDP9I

Types de publication

Journal Article

Langues

jpn

Sous-ensembles de citation

IM

Pagination

145-148

Auteurs

Yuta Ohgi (Y)

Department of CNS Research, New Drug Research Division, Otsuka Pharmaceutical Co., Ltd.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH